Adding the clinical framing, because it changes how the question reads.
Insurance update relevant to cost and coverage: I just got my prior auth approved through UnitedHealthcare after 3 attempts.
What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (sleep apnea + prediabetes), and referencing the SURMOUNT trial data.
If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.
ingrid_STO said:Insurance update relevant to cost and coverage: I just got my prior auth approved through UnitedHealthcare after 3 attempts.
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
ingrid_STO said:Insurance update relevant to cost and coverage: I just got my prior auth approved through UnitedHealthcare after 3 attempts.
ingrid_STO said:...compounded vs brand cost and coverage...
This debate comes up weekly and I think both sides have valid points:
Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable
Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility
My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsingrid_STO said:Insurance update relevant to cost and coverage: I just got my prior auth approved through UnitedHealthcare after 3 attempts.
Bookmarking. The distinction being drawn above is the one nobody else makes.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Tagging this one for the weekly digest.